PepGen Shares Double after Muscle Disease Drug Shows Promise in Trial

PepGen's DM1 drug (PGN-EDODM1) showed a record 53.7% splicing correction following a single dose. Experts expect this fix to lead to functional benefits for patients. A minor, reversible kidney issue was noted in one patient.